Despite a 75% move in 2019 there is still plenty of room to run, indicators are still not oversold and volume remains very high.
Momentum shows no sign of slowing down
Continual upside call buying in the option market.
Promising trial data expected in cancer fighting Drug program.
Moving averages are perfectly formed and fanning out as strength continues.
AVERAGE ANALYSTS PRICE TARGET $28
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
Momentum shows no sign of slowing down
Continual upside call buying in the option market.
Promising trial data expected in cancer fighting Drug program.
Moving averages are perfectly formed and fanning out as strength continues.
AVERAGE ANALYSTS PRICE TARGET $28
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.